These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 37597349)

  • 1. A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy.
    Leist TP; Cole M; Verma S; Keenan A; Le HH
    Mult Scler Relat Disord; 2023 Oct; 78():104917. PubMed ID: 37597349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States.
    Asche CV; Singer ME; Jhaveri M; Chung H; Miller A
    J Manag Care Pharm; 2010; 16(9):703-12. PubMed ID: 21067256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns and Relapses Among Newly Treated Multiple Sclerosis Patients From a Retrospective Claims Analysis.
    Kantor D; Mehta R; Pelletier C; Tian M; Noxon V; Johnson BH; Bonafede M
    Clin Ther; 2020 Nov; 42(11):2136-2147.e3. PubMed ID: 33160682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis.
    Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC
    Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic.
    Coyle PK; Gorritz M; Wade RL; Zhou Z; Khalid S; Maiese EM; Deshpande C; Shao QS
    Mult Scler Relat Disord; 2023 Oct; 78():104881. PubMed ID: 37556938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.
    Ontaneda D; Nicholas J; Carraro M; Zhou J; Hou Q; Babb J; Riester K; Mendoza JP; Livingston T; Jhaveri M
    Mult Scler Relat Disord; 2019 Jan; 27():101-111. PubMed ID: 30368221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.
    Sikirica V; Pliszka SR; Betts KA; Hodgkins P; Samuelson T; Xie J; Erder H; Dammerman R; Robertson B; Wu EQ
    J Manag Care Pharm; 2012; 18(9):676-89. PubMed ID: 23206211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect impact of the COVID-19 pandemic on the care and outcomes of people with MS: A combined survey and insurance claims study.
    Meltzer E; Charron O; Wozny J; Onuorah H; Montague A; Kline AC; Largent A; Krause TM; Freeman L
    Mult Scler Relat Disord; 2023 Dec; 80():105085. PubMed ID: 37931487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data.
    Strand V; Shah R; Atzinger C; Zhou J; Clewell J; Ganguli A; Tundia N
    Curr Med Res Opin; 2020 Jan; 36(1):161-168. PubMed ID: 31433680
    [No Abstract]   [Full Text] [Related]  

  • 11. A Machine Learning Approach to Identify Predictors of Severe COVID-19 Outcome in Patients With Rheumatoid Arthritis.
    Burns SM; Woodworth TS; Icten Z; Honda T; Manjourides J
    Pain Physician; 2022 Nov; 25(8):593-602. PubMed ID: 36375193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consequences of Insurance Denials Among U.S. Patients Prescribed Repository Corticotropin Injection for Acute Exacerbations of Multiple Sclerosis.
    Rice JB; Panaccio MP; White A; Simes M; Billmyer E; Downes N; Niewoehner J; Wan GJ
    Neurol Ther; 2021 Jun; 10(1):149-167. PubMed ID: 33170434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world health plan claims analysis of differences in healthcare utilization and total cost in patients suffering from cluster headaches and those without headache-related conditions.
    Polson M; Lord TC; Evangelatos TM; Lopes M; Santaniello BL
    Am J Manag Care; 2017 Nov; 23(16 Suppl):S295-S299. PubMed ID: 29144719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disease-related and all-cause health care costs of elderly patients with gout.
    Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
    J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Work Productivity Outcomes Associated with Ocrelizumab Compared with Other Disease-Modifying Therapies for Multiple Sclerosis.
    Neuberger EE; Abbass IM; Jones E; Engmann NJ
    Neurol Ther; 2021 Jun; 10(1):183-196. PubMed ID: 33244713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of adherence to disease modifying therapies on long-term clinical and economic outcomes in multiple sclerosis: A claims analysis of real-world data.
    Amezcua L; Livingston T; Hayward B; Zhou J; Williams MJ
    Mult Scler Relat Disord; 2023 Sep; 77():104866. PubMed ID: 37487345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Healthcare resource use and relapses with fingolimod versus natalizumab for treating multiple sclerosis: a retrospective US claims database analysis.
    Bergvall N; Lahoz R; Reynolds T; Korn JR
    Curr Med Res Opin; 2014 Aug; 30(8):1461-71. PubMed ID: 24754349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.
    Blanchette CM; Gutierrez B; Ory C; Chang E; Akazawa M
    J Manag Care Pharm; 2008 Mar; 14(2):176-85. PubMed ID: 18331119
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population.
    Dai D; Sharma A; Phillips AL; Lobo C
    J Health Econ Outcomes Res; 2022; 9(2):125-133. PubMed ID: 36475279
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.